Can boosted atazanavir induce hyperlipotrophy?
Individual variations in glucuronation may result in differences in serum concentrations of atazanavir, resulting in lipodystrophy, illustrating the difficulty in adjusting dosage. We report the case of an HIV/HCV co-infected patient treated with atazanavir.
Dellamonica
P
P
Infectious Diseases Department, Nice University Hospital, Nice Cedex 3, France. infectiologie@chu-nice.fr
D000368:Aged; D000069446:Atazanavir Sulfate; D001663:Bilirubin / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced*; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use
D009842:Oligopeptides; D011480:Protease Inhibitors; D011725:Pyridines; D000069446:Atazanavir Sulfate; D001663:Bilirubin